Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amedisys (AMED) Tops Q2 EPS by 53c, Revs Beat
July 28, 2020 4:11 PM EDTAmedisys (NASDAQ: AMED) reported Q2 EPS of $1.34, $0.53 better than the analyst estimate of $0.81. Revenue for the quarter came in at $485 million versus the consensus estimate of $469.13 million.
Paul B. Kusserow, President and Chief Executive Officer stated, I am very proud of our second quarter results which have allowed us to reissue our... More
